Author

Anabel Clemente-Serrano

Consejo Superior de Investigaciones Científicas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Alba Díaz-Aguilera· 1 shared Alberto Fernández‐MedardeiD· 1 shared Andrea Olarte-San JuaniD· 1 shared Belen Zamora-ValdiviesoiD· 1 shared Carmela GómeziD· 1 shared Dolors ColomeriD· 1 shared Eugenio SantosiD· 1 shared Fermin M. Sanchez-GuijoiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alba Díaz-Aguilera

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano, Belen Zamora-Valdivieso, Sara Pérez-Gutiérrez, Andrea Olarte-San Juan, Alba Díaz-Aguilera, Sonsoles Calvo-Jimenez, Nuria Calzada, Alberto Fernández‐Medarde, Magdalena Sierra, Fermin M. Sanchez-Guijo, Dolors Colomer, Robyn L. Schenk, Marco H. Hofmann, , Eugenio Santos

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

Cell Death and Disease · Aug 12, 2026Peer-reviewedCancer Biology